Loading…
Reported covered position: Chief of Staff, Rep. Allen Boyd
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ALTRIA CLIENT SERVICES LLC · Firm: FORBES-TATE
Issues related to tobacco tax; Issues related to excise tax on tobacco in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to drawback provision in H.R.1 - the One Big Beautiful Bill Act (PL 119-21).
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ALTRIA CLIENT SERVICES LLC · Firm: FORBES-TATE
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
EDWARD D. JONES & CO., L.P. via FORBES-TATE
2026 · third_quarter · Q3
Issues related to retirement security and savings matters; Issues related to small business retirement and retirement savings; Issues related to retirement savings for military spouses; SIMPLE IRAs; Issues related to financial transactions, capital gains, and dividend income taxes; Issues related to senior investor protection matters; Issues related to SEC and DOL standard of care rulemaking; Issues related to partnership tax and IRS Code Section 199A; Issues related to state and local tax provisions for Service Business in the One Big Beautiful Bill Act (PL 119-21).
Source: Senate LDA
| OPTIONS CLEARING CORPORATION (OCC) |
| 49 |
| 2014–2026 |
| AIRLINES FOR AMERICA | 47 | 2016–2026 |
| AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION | 46 | 2013–2024 |
| ALTRIA CLIENT SERVICES LLC | 43 | 2016–2026 |
| HCR MANORCARE | 40 | 2013–2022 |
| IRON MOUNTAIN INFORMATION MANAGEMENT, LLC | 40 | 2017–2026 |
| ORACLE | 40 | 2013–2023 |
| UNITED PARCEL SERVICE | 38 | 2013–2022 |
| ANNALY CAPITAL MANAGEMENT, INC. | 35 | 2013–2021 |
| NOVARTIS, INC. | 35 | 2019–2026 |
| NEW VENTURE FUND | 34 | 2017–2024 |
| WALGREENS CO. | 34 | 2018–2026 |
| COMCAST CORPORATION | 33 | 2012–2020 |
| CTIA - THE WIRELESSS ASSOCIATION | 33 | 2013–2021 |
| SANOFI U.S. | 32 | 2019–2026 |
| INSURED RETIREMENT INSTITUTE | 31 | 2019–2026 |
| VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIES | 31 | 2013–2021 |
| ANHEUSER-BUSCH COMPANIES, INC. | 30 | 2013–2020 |
| ASSOCIATION OF AMERICAN RAILROADS | 30 | 2015–2022 |
| BANK OF AMERICA CORPORATION | 29 | 2015–2022 |
| INDEPENDENT PHARMACY COOPERATIVE | 29 | 2016–2023 |
| LIVE NATION ENTERTAINMENT, INC. | 29 | 2019–2026 |
| ALEXION PHARMACEUTICALS, INC. | 28 | 2020–2026 |
| ASSURED GUARANTY MUNICIPAL CORP. | 28 | 2019–2025 |
| LILLY USA, LLC | 28 | 2020–2026 |
| COALITION FOR CANNABIS POLICY, EDUCATION, AND REGULATION | 27 | 2021–2026 |
| GILEAD SCIENCES, INC. | 27 | 2020–2026 |
| GRAIL, Inc. | 27 | 2020–2026 |
| H&R BLOCK | 27 | 2013–2019 |
| TYSON SHARED SERVICES, INC. | 27 | 2020–2026 |
| CALIFORNIA LIFE SCIENCES ASSOCIATION | 25 | 2020–2026 |
| PELOTON INTERACTIVE, INC. | 25 | 2021–2026 |
| THE NATIONAL FOOTBALL LEAGUE PLAYERS ASSOCIATION | 25 | 2015–2021 |
| UNIVERSAL MUSIC GROUP RECORDINGS, INC. | 25 | 2020–2026 |
| DELOITTE LLP | 23 | 2018–2023 |
| GOBRANDS, INC. | 22 | 2020–2025 |
| HALOZYME THERAPEUTICS, INC. | 22 | 2019–2026 |
| TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION | 22 | 2021–2026 |
| BIO-RAD LABORATORIES | 21 | 2020–2025 |
| EMERGENT BIOSOLUTIONS | 20 | 2019–2023 |
| JOBSOHIO | 20 | 2021–2026 |
| SIEMENS CORPORATION | 20 | 2016–2021 |
| DIRECTV, LLC | 19 | 2022–2026 |
| EDWARD D. JONES & CO., L.P. | 19 | 2022–2026 |
| ABBOTT LABORATORIES | 18 | 2016–2020 |
| LUNDBECK LLC | 18 | 2017–2021 |
| SAREPTA THERAPEUTICS | 18 | 2018–2022 |
| Sorrento Therapeutics, Inc. | 18 | 2017–2021 |
| BAYER CORPORATION | 17 | 2019–2022 |
| HORIZON THERAPEUTICS | 17 | 2020–2023 |
| MERCK | 17 | 2013–2021 |
| PINE STREET STRATEGIES ON BEHALF OF THE CITY OF BIRMINGHAM, ALABAMA | 17 | 2018–2021 |
| BROADCOM LIMITED | 16 | 2018–2021 |
| SECURE IDENTITY, LLC (DBA CLEAR) | 16 | 2019–2023 |
| WITH HONOR ACTION | 16 | 2019–2023 |
| INTERNATIONAL COUNCIL OF SHOPPING CENTERS | 15 | 2020–2023 |
| NATIONAL HOCKEY LEAGUE | 15 | 2018–2021 |
| T-MOBILE | 15 | 2016–2021 |
| TRACTOR SUPPLY CO. | 15 | 2023–2026 |
| VERDE TECHNOLOGIES | 14 | 2019–2022 |
| VOTER PARTICIPATION CENTER | 14 | 2023–2026 |
| AMERICAN HOTEL & LODGING ASSOCIATION | 13 | 2021–2023 |
| AMERICAN INDEPENDENT MEDICAL PRACTICE ASSOCIATION | 13 | 2023–2026 |
| CAPITOL SOLUTIONS ON BEHALF OF BIPARTISAN POLICY CENTER ADVOCACY NETWORK, INC. | 13 | 2019–2022 |
| CITY OF BIRMINGHAM, ALABAMA | 13 | 2023–2026 |
| COMMUNITY FINANCIAL SERVICES ASSOCIATION | 13 | 2013–2015 |
| EYEPOINT PHARMACEUTICALS, INC. | 13 | 2020–2022 |
| NATIONAL NETWORK OF ABORTION FUNDS | 13 | 2014–2016 |
| UNIVERSITY OF SOUTHERN CALIFORNIA | 13 | 2018–2021 |
| ANTIMICROBIAL INNOVATION ALLIANCE | 12 | 2023–2025 |
| ANYWHERE REAL ESTATE INC. | 12 | 2023–2026 |
| INTERSTATE NATURAL GAS ASSOCIATION OF AMERICA | 12 | 2018–2021 |
| LYKOS THERAPEUTICS | 12 | 2023–2024 |
| SPOTIFY USA INC. | 12 | 2015–2017 |
| THE PARTNERSHIP FOR AMERICAS HEALTH CARE FUTURE | 12 | 2019–2021 |
| ALLERGAN USA, INC. | 11 | 2013–2015 |
| NEW VENTURE FUND ON BEHALF OF CENTER FOR SECURE AND MODERN ELECTIONS | 11 | 2021–2023 |
| SPACE EXPLORATION TECHNOLOGIES CORP. | 11 | 2019–2021 |
| AMERICAN COUNCIL OF LIFE INSURERS | 10 | 2012–2015 |
| AUBURN UNIVERSITY | 10 | 2017–2020 |
| BAE SYSTEMS, INC. | 10 | 2018–2020 |
| COMMERCIAL REAL ESTATE FINANCIAL COUNCIL | 10 | 2016–2018 |
| GLADE BROOK CAPITAL PARTNERS, LLC | 10 | 2024–2026 |
| ICE MILLER LLP ON BEHALF OF CITY OF BIRMINGHAM ALABAMA | 10 | 2021–2023 |
| IONIS PHARMACEUTICAL, INC. | 10 | 2024–2026 |
| PRIMMUNE THERAPEUTICS | 10 | 2020–2022 |
| TARGET CORPORATION | 10 | 2020–2022 |
| A PLACE FOR MOM, INC. | 9 | 2018–2020 |
| COALITION FOR APP FAIRNESS | 9 | 2022–2024 |
| LABORATOIRE HRA PHARMA | 9 | 2017–2019 |
| MONUMENTAL SPORTS | 9 | 2024–2026 |
| SAVING AMERICAS FAMILY ENTERPRISES, INC. | 9 | 2021–2023 |
| ABB INC | 8 | 2025–2026 |
| BIPARTISAN POLICY CENTER ACTION | 8 | 2022–2023 |
Issues related to tobacco tax; Issues related to excise tax on tobacco in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to drawback provision in H.R.1 - the One Big Beautiful Bill Act (PL 119-21).
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ALTRIA CLIENT SERVICES LLC · Firm: FORBES-TATE
Issues related to tobacco tax; Issues related to excise tax on tobacco in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to drawback provision in H.R.1 - the One Big Beautiful Bill Act (PL 119-21).
Retirement Fairness for Charities and Educational Institutions Act of 2025
Client: INSURED RETIREMENT INSTITUTE · Firm: FORBES-TATE
Issues related to retirement savings; Issues related to H.R. 1013/S. 424 - The Retirement Fairness for Charities and Educational Institutions Act of 2025; Issues related to DOL Fiduciary rule.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnostic Act of 2025.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037/S. 1500 - Access to Breast Cancer Diagnosis Act of 2025.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnosis Act of 2025.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037/S. 1500 - Access to Breast Cancer Diagnosis Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnostic Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnosis Act of 2025.
Treat and Reduce Obesity Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Treat and Reduce Obesity Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Treat and Reduce Obesity Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Counter-UAS Authority Security, Safety, and Reauthorization Act
Client: LIVE NATION ENTERTAINMENT, INC. · Firm: FORBES-TATE
Issues related to implementation of FAA Reauthorization Act of 2024 (P.L. 118-63), including drone issues; Issues related to drones in H.R. 5061 - Counter-UAS Authority Security, Safety, and Reauthorization Act; Issues related to drones in National Defense Authorization Act for Fiscal Year 2026 (PL 119-60).
Counter-UAS Authority Security, Safety, and Reauthorization Act
Client: LIVE NATION ENTERTAINMENT, INC. · Firm: FORBES-TATE
Issues related to implementation of FAA Reauthorization Act of 2024 (P.L. 118-63), including drone issues; Issues related to drones in H.R. 5061 - Counter-UAS Authority Security, Safety, and Reauthorization Act; Issues related to drones in National Defense Authorization Act for Fiscal Year 2026 (PL 119-60).
Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to Tax Relief for American Families and Workers; Issues related to H.R. 5099 - SAFES Act.
One Big Beautiful Bill Act (PL 119-21); Issues related to Tax Relief for American Families and Workers; Issues related to H.R. 5099 - SAFES Act.
Drug Shortage Compounding Patient Access Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues related to insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Drug Shortage Compounding Patient Access Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Drug Shortage Compounding Patient Access Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Drug Shortage Compounding Patient Access Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Drug Shortage Compounding Patient Access Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Drug Shortage Compounding Patient Access Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues related to insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037/S. 1500 - Access to Breast Cancer Diagnosis Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnostic Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnosis Act of 2025.
Treat and Reduce Obesity Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Treat and Reduce Obesity Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Treat and Reduce Obesity Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues related to insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Retirement Fairness for Charities and Educational Institutions Act of 2025
Client: INSURED RETIREMENT INSTITUTE · Firm: FORBES-TATE
Issues related to retirement savings; Issues related to H.R. 1013/S. 424 - The Retirement Fairness for Charities and Educational Institutions Act of 2025; Issues related to DOL Fiduciary rule.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRACTOR SUPPLY CO. · Firm: FORBES-TATE
H.R. 1 - One Big Beautiful Bill Act; Issues related to Tax Relief for American Families and Workers.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ALTRIA CLIENT SERVICES LLC · Firm: FORBES-TATE
Issues related to tobacco tax; Issues related to excise tax on tobacco in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to drawback provision in H.R.1 - the One Big Beautiful Bill Act (PL 119-21).
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues related to the report accompanying the FY 26 Senate Labor-HHS-Education Appropriations; Issues related to Rx drug pricing in H.R. 1 - the One Big Beautiful Bill Act.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRACTOR SUPPLY CO. · Firm: FORBES-TATE
H.R. 1 - One Big Beautiful Bill Act; Issues related to Tax Relief for American Families and Workers.
Retirement Fairness for Charities and Educational Institutions Act of 2025
Client: INSURED RETIREMENT INSTITUTE · Firm: FORBES-TATE
Issues related to retirement savings; Issues related to H.R. 1013 - The Retirement Fairness for Charities and Educational Institutions Act of 2025; Issues related to DOL Fiduciary rule.
Retirement Fairness for Charities and Educational Institutions Act of 2025
Client: INSURED RETIREMENT INSTITUTE · Firm: FORBES-TATE
Issues related to retirement savings; Issues related to H.R. 1013/S. 424 - The Retirement Fairness for Charities and Educational Institutions Act of 2025; Issues related to DOL Fiduciary rule.
Retirement Fairness for Charities and Educational Institutions Act of 2025
Client: INSURED RETIREMENT INSTITUTE · Firm: FORBES-TATE
Issues related to retirement savings; Issues related to H.R. 1013/S. 424 - The Retirement Fairness for Charities and Educational Institutions Act of 2025; Issues related to DOL Fiduciary rule.
Freedom from Intimidation in Elections Act
Client: SHEIN TECHNOLOGY LLC · Firm: FORBES-TATE
Issues related to legislative and regulatory issues impacting the fashion and on-demand apparel industry, e-retailing and overall online competition, including trade related matters and sustainability; General education regarding SHEIN's presence, operating footprint, and economic impact in the United States; Issues related to trade provision in H.R. 8070, the Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025 and H.R. 10545, the American Relief Act of 2025; Issues related to de minimis reform.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to retirement security and savings matters; Issues related to small business retirement and retirement savings; Issues related to retirement savings for military spouses; SIMPLE IRAs; Issues related to financial transactions, capital gains, and dividend income taxes; Issues related to senior investor protection matters; Issues related to SEC and DOL standard of care rulemaking; Issues related to partnership tax and IRS Code Section 199A; Issues related to banking services.
Issues related to bank chartering.
Issues related to retirement security and savings matters; Issues related to small business retirement and retirement savings; Issues related to retirement savings for military spouses; SIMPLE IRAs; Issues related to financial transactions, capital gains, and dividend income taxes; Issues related to senior investor protection matters; Issues related to SEC and DOL standard of care rulemaking; Issues related to partnership tax and IRS Code Section 199A.
Filing targets: SENATE
2026 · third_quarter · Q3
Issues related to pharmacies, pharmacists, and Medicare reimbursement; Issues related to the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to Pharmacy Benefit Managers.
Issues related to pharmacies, pharmacists, Medicare reimbursement, and opioids; Issues related to vaccines; Issues related to the FDA certification process; Issues related to Pharmacy Benefit Managers.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VOTER PARTICIPATION CENTER via FORBES-TATE
2026 · third_quarter · Q3
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Issues related to legislation governing regulation of prediction markets.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON via FORBES-TATE
2026 · third_quarter · Q3
Issues related to the 340B Drug Pricing Program.
Issues related to the 340B Drug Pricing Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TYSON SHARED SERVICES, INC. via FORBES-TATE
2026 · third_quarter · Q3
Issues related to livestock and food pricing.
Issues related to workplace standards; Issues related to livestock and food pricing.
Issues related to workplace standards; Issues related to livestock and food pricing.
Issues related to workplace standards; Issues related to livestock and food pricing; Issues related to labor union work condition negotiation.
Issues related to Xylazine usage.
COMPASS, INC. D/B/A COMPASS INTERNATIONAL HOLDINGS via FORBES-TATE
2026 · third_quarter · Q3
Issues related to real estate.
Issues related to real estate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE CURE COALITION via FORBES-TATE
2026 · third_quarter · Q3
Issues related to medical innovation and drug development.
Issues related to medical innovation and drug development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION via FORBES-TATE
2026 · third_quarter · Q3
Issues related to regulations that would restrict operations of farm bureau health insurance plans.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TRACTOR SUPPLY CO. via FORBES-TATE
2026 · third_quarter · Q3
Issues related to tariffs and trade.
Issues related to federal land use.
Issues related to tariffs and trade.
SYDNEXIS via FORBES-TATE
2026 · third_quarter · Q3
Issues related to ophthalmic treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STATE OF NORTH CAROLINA via FORBES-TATE
2026 · third_quarter · Q3
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
PELOTON INTERACTIVE, INC. via FORBES-TATE
2026 · third_quarter · Q3
Issues related to commerce, tax, trade and health.
Issues related to commerce, tax, trade and health.
Issues related to commerce, tax, trade and health.
SUMRELL SUGG OBO CAROLINAEAST HEALTH SYSTEM via FORBES-TATE
2026 · third_quarter · Q3
Issues related to hospital reimbursement.
Issues related to hospital reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via FORBES-TATE
2026 · third_quarter · Q3
Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.
Issues related to data exclusivity under the United States Mexico Canada Agreement (USMCA); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
SONY INTERACTIVE ENTERTAINMENT LLC via FORBES-TATE
2026 · third_quarter · Q3
Issues related to antitrust, competition, and the gaming industry.
Issues related to gaming-related tariff policies.
Issues related to operational improvements for legislation related to issues involving online safety and accountability.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS, INC. via FORBES-TATE
2026 · third_quarter · Q3
Issues related to prescription drug pricing; Issues related to pharmaceutical intellectual property; Issues related to international trade; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037/S. 1500 - Access to Breast Cancer Diagnosis Act of 2025.
NATIONAL CABLE & TELECOMMUNICATIONS ASSOCIATION via FORBES-TATE
2026 · third_quarter · Q3
Issues related to rural broadband coverage; Issues related to Rural Utilities Service Broadband; Issues related to privacy; Issues related to broadband mapping.
Issues related to infrastructure; Issues related to broadband.
Issues related to cyber intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Issues related to prescription drug pricing; Issues related to Section 340B of the Public Health Service Act (PL 78-410); Drug pricing issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to flu and RSV vaccines.
Issues related to prescription drug pricing, including the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Section 340B of the Public Health Service Act (PL 78-410); Issues related to pharmacy benefit managers.
Issues related to Orphan Drug Tax Credit; Issues related to the excise tax for the Vaccine Injury Compensation Fund.
REGISTER AMERICA via FORBES-TATE
2026 · third_quarter · Q3
Issues related to voter registration programs.
Filing targets: HOUSE OF REPRESENTATIVES
ELI LILLY AND COMPANY FKA LILLY USA, LLC via FORBES-TATE
2026 · third_quarter · Q3
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues related to the report accompanying the FY 26 Senate Labor-HHS-Education Appropriations; Issues related to Rx drug pricing in the One Big Beautiful Bill Act (PL 119-21).
JOBSOHIO via FORBES-TATE
2026 · third_quarter · Q3
Issues related to the implementation of the CHIPS and Science Act of 2022 (PL 117-167).
Issues related to economic development, job creation, job retention, job training, workforce development, and the retention of current business, and recruitment of new business to Ohio.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENENTECH via FORBES-TATE
2026 · third_quarter · Q3
Issues related to international tax and R&D amortization credit in the Tax Cuts and Jobs Act (PL 115-97); Issues related to tax; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Issues related to funding of the strategic national stockpile; Issues related to the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Issues regarding the Center for Medicare and Medicaid Innovation; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
ALTRIA CLIENT SERVICES LLC via FORBES-TATE
2026 · third_quarter · Q3
Issues related to tobacco tax; Issues related to excise tax on tobacco in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to drawback provision in H.R.1 - the One Big Beautiful Bill Act (PL 119-21).
Issues related to the International Trade Commission.
Issues related to flavors in Tobacco products; Conversations concerning federal appropriations policy related to FDA clarity on CBD; Issues related to unregulated vape products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CITY OF BIRMINGHAM, ALABAMA via FORBES-TATE
2026 · third_quarter · Q3
FY25/26 Appropriations - Homeland/FEMA, CJS, THUD, E&W; Issues related to crime; Issues related to transportation infrastructure; Issues related to flood mitigation; Issues related to waterways infrastructure; Issues related to economic development; Issues related to housing.
FY25/26 Appropriations - Homeland/FEMA, CJS, THUD, E&W; Issues related to crime; Issues related to transportation infrastructure; Issues related to flood mitigation; Issues related to waterways infrastructure; Issues related to economic development; Issues related to housing.
FY25/26 Appropriations - Homeland/FEMA, CJS, THUD, E&W; Issues related to crime; Issues related to transportation infrastructure; Issues related to flood mitigation; Issues related to waterways infrastructure; Issues related to economic development; Issues related to housing.
CALIFORNIA LIFE SCIENCES ASSOCIATION via FORBES-TATE
2026 · third_quarter · Q3
Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Pharmacy Benefit Managers.
AMGEN USA, INC. via FORBES-TATE
2026 · third_quarter · Q3
Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues related to the implementation of international tax and tax reform in the Tax Cuts and Jobs Act (PL 115-97); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
AMERICAN INDEPENDENT MEDICAL PRACTICE ASSOCIATION via FORBES-TATE
2026 · third_quarter · Q3
Issues related to healthcare; Issues related to provider reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALEXION PHARMACEUTICALS, INC. via FORBES-TATE
2026 · third_quarter · Q3
Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to orphan drug tax credit; Issues related to rare disease; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to orphan drugs under the Drug Price Negotiation Program.
Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to the Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AIRLINES FOR AMERICA via FORBES-TATE
2026 · third_quarter · Q3
Issues related to aviation system funding and management related to Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (PL 119-37); Issues related to aviation systemsoperations related to consideration of National Defense Authorization Act for Fiscal Year 2026 (PL 119-60).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABB INC. via FORBES-TATE
2026 · third_quarter · Q3
Issues related to IRA funding provisions; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to IRA funding provisions; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to IRA funding provisions; Issues related to the One Big Beautiful Bill Act (PL 119-21).
NORTHPORT HEALTH SERVICES via FORBES-TATE
2026 · third_quarter · Q3
Healthcare legislative issues, including Medicare, Medicaid, and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, and post-acute care reform.
Healthcare legislative issues, including Medicare, Medicaid, and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, post-acute care reform, the Older Americans Act (PL 89-73), intergenerational therapy; Issues related to Medicare requirements for participation.
Healthcare legislative issues, including Medicare, Medicaid, and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, and post-acute care reform.
MONUMENTAL SPORTS via FORBES-TATE
2026 · third_quarter · Q3
Issues related to sports.
Issues related to the funding of the District of Columbia.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IRON MOUNTAIN INFORMATION MANAGEMENT, LLC via FORBES-TATE
2026 · third_quarter · Q3
Issues related to privacy and data security legislation related to consumer data breach notification; Issues related to data centers.
Issues related to federal records management; Issues related to House Transportation and Infrastructure Committee Resolution regarding Prospectus PPA-FBC-BO17; Issues related to federal record storage; Issues related to federal records management for the VA; Issues related to data centers.
Issues related to Department of Defense operations, including records management; Issues related to the implementation of the American Rescue Plan Act of 2021 (PL 117-2); Issues related to data centers.
IONIS PHARMACEUTICAL, INC. via FORBES-TATE
2026 · third_quarter · Q3
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IMAGINE LEARNING via FORBES-TATE
2026 · third_quarter · Q3
Issues related to artificial intelligence and education.
Issues related to funding for Title I programs; Issues related to Title I and digital education programs.
Issues related to digital learning in K-12 education, student privacy, and digital education; Issues related to funding for Title 1 programs.
Filing targets: Education, Dept of, HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Healthcare issues regarding oncology and early multi-cancer detection, including diagnostics and screening; Medicare issues regarding oncology and early multi-cancer detection, including diagnostics and screening.
Healthcare issues regarding oncology and early multi-cancer detection, including diagnostics and screening; Medicare issues regarding oncology and early multi-cancer detection, including diagnostics and screening.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLADE BROOK CAPITAL PARTNERS, LLC via FORBES-TATE
2026 · third_quarter · Q3
Issues related to software, tech, and e-commerce.
Issues related to software, tech, and e-commerce.
Issues related to software, tech, and e-commerce.
GILEAD SCIENCES, INC. via FORBES-TATE
2026 · third_quarter · Q3
Issues related to healthcare, including improving patient access to advanced immunology therapies; Issues related to policies affecting biopharma products pricing, coverage and access in Medicare and Medicaid; Issues related to funding for HIV and HCV screening, linkage to care and treatment; Issues related to breast cancer screening.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2026 · third_quarter · Q3
Issues related to consumer privacy; Issues related to media ownership; Issues related to carriage disputes.
Issues related to retransmission consent reform; Issues related to consumer privacy and children online safety; Issues related to media ownership.
Issues related to tax relief for American families and workers.
DIGESTIVE HEALTH PHYSICIANS ASSOCIATION via FORBES-TATE
2026 · third_quarter · Q3
Issues related to healthcare data; Issues related to provider reimbursement.
Issues related to Medicare Advantage; Issues related to physician payments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ANYWHERE REAL ESTATE INC. via FORBES-TATE
2026 · second_quarter · 2@
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON via FORBES-TATE
2026 · third_quarter · RR
Issues related to the 340B Drug Pricing Program.
Issues related to the 340B Drug Pricing Program.
2026 · second_quarter · Q2
Issues related to prescription drug pricing; Issues related to Section 340B of the Public Health Service Act (PL 78-410); Drug pricing issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to flu and RSV vaccines.
Issues related to prescription drug pricing, including the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Section 340B of the Public Health Service Act (PL 78-410); Issues related to pharmacy benefit managers.
Issues related to orphan drug tax credit; Issues related to the excise tax for the Vaccine Injury Compensation Fund.
IONIS PHARMACEUTICAL, INC. via FORBES-TATE
2026 · second_quarter · Q2
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN USA, INC. via FORBES-TATE
2026 · second_quarter · Q2
Issues related to the implementation of international tax and tax reform in the Tax Cuts and Jobs Act (PL 115-97); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
REGISTER AMERICA via FORBES-TATE
2026 · second_quarter · Q2
Issues related to voter registration programs.
Filing targets: HOUSE OF REPRESENTATIVES
CALIFORNIA LIFE SCIENCES ASSOCIATION via FORBES-TATE
2026 · second_quarter · Q2
Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Pharmacy Benefit Managers.
Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Pharmacy Benefit Managers.
TYSON SHARED SERVICES, INC. via FORBES-TATE
2026 · second_quarter · Q2
Issues related to workplace standards; Issues related to livestock and food pricing.
Issues related to workplace standards; Issues related to livestock and food pricing.
Issues related to Xylazine usage.
CITY OF BIRMINGHAM, ALABAMA via FORBES-TATE
2026 · second_quarter · Q2
FY25/26 Appropriations - Homeland/FEMA, CJS, THUD, E&W; Issues related to crime; Issues related to transportation infrastructure; Issues related to flood mitigation; Issues related to waterways infrastructure; Issues related to economic development; Issues related to housing.
FY25/26 Appropriations - Homeland/FEMA, CJS, THUD, E&W; Issues related to crime; Issues related to transportation infrastructure; Issues related to flood mitigation; Issues related to waterways infrastructure; Issues related to economic development; Issues related to housing.
FY25/26 Appropriations - Homeland/FEMA, CJS, THUD, E&W; Issues related to crime; Issues related to transportation infrastructure; Issues related to flood mitigation; Issues related to waterways infrastructure; Issues related to economic development; Issues related to housing.
AMERICAN INDEPENDENT MEDICAL PRACTICE ASSOCIATION via FORBES-TATE
2026 · second_quarter · Q2
Issues related to healthcare; Issues related to provider reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR CANNABIS POLICY, EDUCATION, AND REGULATION via FORBES-TATE
2026 · second_quarter · Q2
Issues pertaining to government-wide federal regulation of cannabis.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE CURE COALITION via FORBES-TATE
2026 · second_quarter · Q2
Issues related to medical innovation and drug development.
Issues related to medical innovation and drug development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALEXION PHARMACEUTICALS, INC. via FORBES-TATE
2026 · second_quarter · Q2
Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to orphan drug tax credit; Issues related to rare disease; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to orphan drugs under the Drug Price Negotiation Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION via FORBES-TATE
2026 · second_quarter · Q2
Issues related to regulations that would restrict operations of farm bureau health insurance plans.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
IMAGINE LEARNING via FORBES-TATE
2026 · second_quarter · Q2
Issues related to funding for Title I programs; Issues related to Title I and digital education programs.
Issues related to digital learning in K-12 education, student privacy, and digital education; Issues related to funding for Title 1 programs.
Issues related to artificial intelligence and education.
Filing targets: Education, Dept of, HOUSE OF REPRESENTATIVES, SENATE
SYDNEXIS via FORBES-TATE
2026 · second_quarter · Q2
Issues related to ophthalmic treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSAL MUSIC GROUP RECORDINGS, INC. via FORBES-TATE
2026 · second_quarter · Q2
Issues related to copyright and licensing; Issues related to artificial intelligence.
Issues related to copyright and licensing; Issues related to artificial intelligence; Issues related to creator rights.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AIRLINES FOR AMERICA via FORBES-TATE
2026 · second_quarter · Q2
Issues related to aviation system funding and management related to Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (PL 119-37); Issues related to aviation systemsoperations related to consideration of National Defense Authorization Act for Fiscal Year 2026 (PL 119-60).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STRATHSPEY CROWN HOLDINGS, LLC via FORBES-TATE
2026 · second_quarter · Q2
Issues related to CMS coverage decisions and issues related to healthcare reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STATE OF NORTH CAROLINA via FORBES-TATE
2026 · second_quarter · Q2
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
2026 · second_quarter · Q2
Healthcare issues regarding oncology and early multi-cancer detection, including diagnostics and screening; Medicare issues regarding oncology and early multi-cancer detection, including diagnostics and screening.
Healthcare issues regarding oncology and early multi-cancer detection, including diagnostics and screening; Medicare issues regarding oncology and early multi-cancer detection, including diagnostics and screening.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SUMRELL SUGG OBO CAROLINAEAST HEALTH SYSTEM via FORBES-TATE
2026 · second_quarter · Q2
Issues related to hospital reimbursement.
Issues related to hospital reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VOTER PARTICIPATION CENTER via FORBES-TATE
2026 · second_quarter · Q2
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Issues related to pharmacies, pharmacists, and Medicare reimbursement; Issues related to the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to Pharmacy Benefit Managers.
Issues related to pharmacies, pharmacists, Medicare reimbursement, and opioids; Issues related to vaccines; Issues related to the FDA certification process; Issues related to Pharmacy Benefit Managers.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SONY INTERACTIVE ENTERTAINMENT LLC via FORBES-TATE
2026 · second_quarter · Q2
Issues related to gaming-related tariff policies.
Issues related to antitrust, competition, and the gaming industry.
Issues related to operational improvements for legislation related to issues involving online safety and accountability.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLADE BROOK CAPITAL PARTNERS, LLC via FORBES-TATE
2026 · second_quarter · Q2
Issues related to software, tech, and e-commerce.
Issues related to software, tech, and e-commerce.
Issues related to software, tech, and e-commerce.
GILEAD SCIENCES, INC. via FORBES-TATE
2026 · second_quarter · Q2
Issues related to healthcare, including improving patient access to advanced immunology therapies; Issues related to policies affecting biopharma products pricing, coverage and access in Medicare and Medicaid; Issues related to funding for HIV and HCV screening, linkage to care and treatment; Issues related to breast cancer screening.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
EDWARD D. JONES & CO., L.P. via FORBES-TATE
2026 · second_quarter · Q2
Issues related to retirement security and savings matters; Issues related to small business retirement and retirement savings; Issues related to retirement savings for military spouses; SIMPLE IRAs; Issues related to financial transaction, capital gains, and dividend income taxes; Issues related to senior investor protection matters; Issues related to SEC and DOL standard of care rulemaking; Issues related to partnership tax and IRS Code Section 199A.
Issues related to bank chartering.
Issues related to retirement security and savings matters; Issues related to small business retirement and retirement savings; Issues related to retirement savings for military spouses; SIMPLE IRAs; Issues related to financial transaction, capital gains, and dividend income taxes; Issues related to senior investor protection matters; Issues related to SEC and DOL standard of care rulemaking; Issues related to partnership tax and IRS Code Section 199A; Issues related to banking services.
OPTIONS CLEARING CORPORATION (OCC) via FORBES-TATE
2026 · second_quarter · Q2
Issues related to financial services and tax.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Issues related to tax relief for American families and workers.
Issues related to consumer privacy and children online safety; Issues related to media ownership.
Issues related to retransmission consent reform; Issues related to consumer privacy and children online safety; Issues related to media ownership.
NORTHPORT HEALTH SERVICES via FORBES-TATE
2026 · second_quarter · Q2
Healthcare legislative issues, including Medicare, Medicaid, and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, post-acute care reform, the Older Americans Act (PL 89-73), intergenerational therapy; Issues related to Medicare requirements for participation.
Healthcare legislative issues, including Medicare, Medicaid, and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, and post-acute care reform.
Healthcare legislative issues, including Medicare, Medicaid, and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, and post-acute care reform.
DIGESTIVE HEALTH PHYSICIANS ASSOCIATION via FORBES-TATE
2026 · second_quarter · Q2
Issues related to healthcare data; Issues related to provider reimbursement.
Issues related to Medicare Advantage; Issues related to physician payments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABB INC. via FORBES-TATE
2026 · second_quarter · Q2
Issues related to tariffs and trade; Issues related to Section 232 and copper.
Issues related to IRA funding provisions; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to IRA funding provisions; Issues related to the One Big Beautiful Bill Act (PL 119-21).
MONUMENTAL SPORTS via FORBES-TATE
2026 · second_quarter · Q2
Issues related to sports.
Issues related to the funding of the District of Columbia.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TRACTOR SUPPLY CO. via FORBES-TATE
2026 · second_quarter · Q2
One Big Beautiful Bill Act (PL 119-21); Issues related to Tax Relief for American Families and Workers; Issues related to H.R. 5099 - SAFES Act.
Issues related to federal land use.
Issues related to tariffs and trade.
PHRMA via FORBES-TATE
2026 · second_quarter · Q2
Issues pertaining to prescription drug pricing; Medicare Part D; Importation of drugs; Issues related to 340b; Issues related to Drug Price Competition and Patent Term Restoration Act (PL 98-417); Issues related to Section 340B of the Public Health Service Act; Issues related to Consolidated Appropriations Act, 2022 (PL 117-103); Issues related to prescription drug user fee agreement; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to pharmacy benefit managers.
Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.
PELOTON INTERACTIVE, INC. via FORBES-TATE
2026 · second_quarter · Q2
Issues related to commerce, tax, trade and health.
Issues related to commerce, tax, trade and health.
Issues related to commerce, tax, trade and health.
NOVARTIS, INC. via FORBES-TATE
2026 · second_quarter · Q2
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnosis Act of 2025.
Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
IRON MOUNTAIN INFORMATION MANAGEMENT, LLC via FORBES-TATE
2026 · second_quarter · Q2
Issues related to Department of Defense operations, including records management; Issues related to the implementation of the American Rescue Plan Act of 2021 (PL 117-2).
Issues related to privacy and data security legislation related to consumer data breach notification.
Issues related to consolidation of federal data centers under the Federal Information Technology Acquisition and Reform Act (PL 113-291); Issues related to federal records management for the VA.
NATIONAL CABLE & TELECOMMUNICATIONS ASSOCIATION via FORBES-TATE
2026 · second_quarter · Q2
Issues related to infrastructure; Issues related to broadband.
Issues related to cyber intelligence.
Issues related to rural broadband coverage; Issues related to Rural Utilities Service Broadband; Issues related to privacy; Issues related to broadband mapping.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY FKA LILLY USA, LLC via FORBES-TATE
2026 · second_quarter · Q2
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
JOBSOHIO via FORBES-TATE
2026 · second_quarter · Q2
Issues related to the implementation of the CHIPS and Science Act of 2022 (PL 117-167).
Issues related to economic development, job creation, job retention, job training, workforce development, and the retention of current business, and recruitment of new business to Ohio.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENENTECH via FORBES-TATE
2026 · second_quarter · Q2
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D; Issues related to prescription drug user fee agreement; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.
Issues related to the 340B Drug Pricing Program.
Intellectual property and process patent related issues.
ALTRIA CLIENT SERVICES LLC via FORBES-TATE
2026 · second_quarter · Q2
Issues related to the International Trade Commission.
Issues related to flavors in Tobacco products; Conversations concerning federal appropriations policy related to FDA clarity on CBD; Issues related to unregulated vape products.
Issues related to tobacco tax; Issues related to excise tax on tobacco in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to drawback provision in H.R.1 - the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LIVE NATION ENTERTAINMENT, INC. via FORBES-TATE
2026 · second_quarter · 2T
Issues related to safety and security surrounding Venues.
Issues related to transparency and accounting related to ticket sales pricing; Issues related to competition enforcement.
Issues related to transparency and accountability to ticket sales pricing.
2026 · third_quarter · RR
Issues related to legislation governing regulation of prediction markets.
COMPASS, INC. D/B/A COMPASS INTERNATIONAL HOLDINGS via FORBES-TATE
2026 · third_quarter · RR
Issues related to real estate.
Issues related to real estate.
ANYWHERE REAL ESTATE INC. via FORBES-TATE
2026 · second_quarter · 2T
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Issues related to pharmacies, pharmacists, Medicare reimbursement, and opioids; Issues related to vaccines; Issues related to the FDA certification process; Issues related to Pharmacy Benefit Managers.
Issues related to pharmacies, pharmacists, and Medicare reimbursement; Issues related to the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to Pharmacy Benefit Managers.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VOTER PARTICIPATION CENTER via FORBES-TATE
2026 · first_quarter · Q1
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSAL MUSIC GROUP RECORDINGS, INC. via FORBES-TATE
2026 · first_quarter · Q1
Issues related to copyright and licensing; Issues related to artificial intelligence.
Issues related to copyright and licensing; Issues related to artificial intelligence; Issues related to creator rights.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TYSON SHARED SERVICES, INC. via FORBES-TATE
2026 · first_quarter · Q1
Issues related to Xylazine usage.
Issues related to workplace standards; Issues related to livestock and food pricing.
Issues related to workplace standards; Issues related to livestock and food pricing.
THE CURE COALITION via FORBES-TATE
2026 · first_quarter · Q1
Issues related to medical innovation and drug development.
Issues related to medical innovation and drug development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION via FORBES-TATE
2026 · first_quarter · Q1
Issues related to regulations that would restrict operations of farm bureau health insurance plans.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
STRATHSPEY CROWN HOLDINGS, LLC via FORBES-TATE
2026 · first_quarter · Q1
Issues related to CMS coverage decisions and issues related to healthcare reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SUMRELL SUGG OBO CAROLINAEAST HEALTH SYSTEM via FORBES-TATE
2026 · first_quarter · Q1
Issues related to hospital reimbursement.
Issues related to hospital reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SONY INTERACTIVE ENTERTAINMENT LLC via FORBES-TATE
2026 · first_quarter · Q1
Issues related to gaming-related tariff policies.
Issues related to antitrust, competition, and the gaming industry.
Issues related to operational improvements for legislation related to issues involving online safety and accountability.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Issues related to orphan drug tax credit; Issues related to the excise tax for the Vaccine Injury Compensation Fund.
Issues related to prescription drug pricing; Issues related to Section 340B of the Public Health Service Act (P.L. 78-410); Drug pricing issues related to the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to flu and RSV vaccines.
Issues related to prescription drug pricing, including the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to Section 340B of the Public Health Service Act (P.L. 78-410); Issues related to pharmacy benefit managers.
REGISTER AMERICA via FORBES-TATE
2026 · first_quarter · Q1
Issues related to voter registration programs.
Filing targets: HOUSE OF REPRESENTATIVES
Issues related to workplace standards; Issues related to livestock and food pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to Tax Relief for American Families and Workers; Issues related to H.R. 5099 - SAFES Act.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
Filing targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to commerce, tax, trade and health.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE
Issues related to Direct to Consumer (DTC) Advertising; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues pertaining to prescription drug pricing; Medicare Part D; Importation of drugs; Issues related to 340b; Issues related to Drug Price Competition and Patent Term Restoration Act (PL 98-417); Issues related to Section 340B of the Public Health Service Act; Issues related to Consolidated Appropriations Act, 2022 (PL 117-103); Issues related to prescription drug user fee agreement; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to pharmacy benefit managers.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to intellectual property and process patent.
Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D; Issues related to prescription drug user fee agreement; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.
Issues related to the 340B Drug Pricing Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Pharmacy Benefit Managers.
Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Pharmacy Benefit Managers; Issues related to transitional coverage of emerging technologies.
Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to tariffs and trade; Issues related to Section 232 and copper.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to consolidation of federal data centers under the Federal Information Technology Acquisition and Reform Act (PL 113-291); Issues related to federal records management for the VA; Issues related to data centers.
Issues related to tax treatment of REITS (Real Estate Investment Trust); Issues related to data centers.
Issues related to federal records management; Issues related to federal background checks; Issues related to data centers.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to software, tech, and e-commerce.
Issues related to software, tech, and e-commerce.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to consumer privacy; Issues related to media ownership; Issues related to privacy; Issues related to digital television services including retransmission consent reform.
Issues related to consumer privacy and children online safety; Issues related to media ownership.
Issues related to consumer privacy; Issues related to media ownership.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Pharmacy Benefit Managers; Issues related to transitional coverage of emerging technologies.
Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to livestock and food pricing.
Issues related to workplace standards; Issues related to livestock and food pricing; Issues related to labor union work condition negotiation.
Issues related to workplace standards; Issues related to livestock and food pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
Filing targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to software, tech, and e-commerce.
Issues related to software, tech, and e-commerce.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to retirement security and savings matters; Issues related to small business retirement and retirement savings; Issues related to retirement savings for military spouses; SIMPLE IRAs; Issues related to financial transaction, capital gains, and dividend income taxes; Issues related to senior investor protection matters; Issues related to SEC and DOL standard of care rulemaking; Issues related to partnership tax and IRS Code Section 199A; Issues related to state and local tax provisions for Service Business in the One Big Beautiful Bill Act (PL 119-21).
Filing targets: SENATE
Issues related to consumer privacy; Issues related to media ownership.
Issues related to consumer privacy; Issues related to media ownership; Issues related to carriage disputes.
Issues related to consumer privacy; Issues related to media ownership; Issues related to privacy; Issues related to digital television services including retransmission consent reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to IRA funding provisions; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to tariffs and trade.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
Issues related to data exclusivity under the United States Mexico Canada Agreement (USMCA); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues related to Direct to Consumer (DTC) Advertising; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to commerce, tax, trade and health.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to pharmaceutical intellectual property; Issues related to international trade; Issues related to the 340b program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to tax treatment of REITS (Real Estate Investment Trust).
Issues related to federal records management; Issues related to House Transportation and Infrastructure Committee Resolution regarding Prospectus PPA-FBC-BO17; Issues related to federal record storage; Issues related to federal records management for the VA.
Issues related to federal records management; Issues related to federal background checks.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the report accompanying the FY 26 Senate Labor-HHS-Education Appropriations; Issues related to Rx drug pricing in the One Big Beautiful Bill Act (P.L. 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to funding of the strategic national stockpile; Issues related to the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Issues related to international tax and R&D amortization credit in the Tax Cuts and Jobs Act (PL 115-97); Issues related to tax; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Issues regarding the Center for Medicare and Medicaid Innovation; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to implementation of FAA Reauthorization Act of 2024 (P.L. 118-63), including drone issues; Issues related to drones in H.R. 5061 - Counter-UAS Authority Security, Safety, and Reauthorization Act; Issues related to drones in National Defense Authorization Act for Fiscal Year 2026 (PL 119-60).
Filing targets: Federal Aviation Administration (FAA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to workplace standards; Issues related to livestock and food pricing.
Issues related to livestock and food pricing.
Issues related to workplace standards; Issues related to livestock and food pricing; Issues related to labor union work condition negotiation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE